DE60022478T2 - Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen - Google Patents

Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen Download PDF

Info

Publication number
DE60022478T2
DE60022478T2 DE60022478T DE60022478T DE60022478T2 DE 60022478 T2 DE60022478 T2 DE 60022478T2 DE 60022478 T DE60022478 T DE 60022478T DE 60022478 T DE60022478 T DE 60022478T DE 60022478 T2 DE60022478 T2 DE 60022478T2
Authority
DE
Germany
Prior art keywords
vegf
growth factor
penis
vascular endothelial
endothelial growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60022478T
Other languages
German (de)
English (en)
Other versions
DE60022478D1 (de
Inventor
Ridwan Shabsigh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Application granted granted Critical
Publication of DE60022478D1 publication Critical patent/DE60022478D1/de
Publication of DE60022478T2 publication Critical patent/DE60022478T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D27/00—Stirring devices for molten material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Mechanical Engineering (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60022478T 1999-01-21 2000-01-21 Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen Expired - Fee Related DE60022478T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/234,591 US6706682B2 (en) 1999-01-21 1999-01-21 Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US234591 1999-01-21
PCT/US2000/001535 WO2000043029A1 (en) 1999-01-21 2000-01-21 Uses of vascular endothelial growth factor in the treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
DE60022478D1 DE60022478D1 (de) 2005-10-13
DE60022478T2 true DE60022478T2 (de) 2006-06-22

Family

ID=22882011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022478T Expired - Fee Related DE60022478T2 (de) 1999-01-21 2000-01-21 Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen

Country Status (9)

Country Link
US (2) US6706682B2 (enExample)
EP (1) EP1150698B1 (enExample)
JP (1) JP2003501345A (enExample)
AT (1) ATE303818T1 (enExample)
AU (1) AU2623700A (enExample)
CA (1) CA2360058A1 (enExample)
DE (1) DE60022478T2 (enExample)
DK (1) DK1150698T3 (enExample)
WO (1) WO2000043029A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
CA2386480A1 (en) * 1999-10-01 2001-04-12 Julie M. Miller A method of treating erectile dysfunction
US20020032153A1 (en) * 2000-03-10 2002-03-14 Whitehouse Martha Jo Methods and compositions for the treatment and prevention of erectile dysfunction
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2007138590A2 (en) * 2006-05-30 2007-12-06 Yossi Gross Implantable pump for drug delivery to treat erectile dysfunction
US8152711B2 (en) * 2007-03-21 2012-04-10 Yossi Gross Implantable peristaltic pump to treat erectile dysfunction
US7818062B2 (en) * 2008-01-31 2010-10-19 Ed Tech Medical Ltd. Peristaltic pump for treatment of erectile dysfunction
US20120183519A1 (en) * 2011-01-13 2012-07-19 Biomet Biologics, Llc Treatment of erectile dysfunction using platelet-rich plasma
WO2016112049A1 (en) 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Angiogenic treatment of ischemic heart disease
CA2976675A1 (en) * 2015-02-16 2016-08-25 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1999056785A2 (en) 1998-05-01 1999-11-11 University Of Pittsburgh Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction
AU4077499A (en) 1998-05-15 1999-12-06 Glaxo Group Limited Infrared thermography
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
CA2386480A1 (en) 1999-10-01 2001-04-12 Julie M. Miller A method of treating erectile dysfunction

Also Published As

Publication number Publication date
CA2360058A1 (en) 2000-07-27
EP1150698B1 (en) 2005-09-07
ATE303818T1 (de) 2005-09-15
US6706682B2 (en) 2004-03-16
JP2003501345A (ja) 2003-01-14
DE60022478D1 (de) 2005-10-13
EP1150698A1 (en) 2001-11-07
WO2000043029A1 (en) 2000-07-27
US20030124094A1 (en) 2003-07-03
US20040048800A1 (en) 2004-03-11
AU2623700A (en) 2000-08-07
EP1150698A4 (en) 2003-01-29
DK1150698T3 (da) 2006-01-16

Similar Documents

Publication Publication Date Title
Yan et al. Insulin‐like growth factor‐1 is an endogenous mediator of focal ischemia‐induced neural progenitor proliferation
EP1443955B1 (en) Pdgf-bb for the treatment of parkinson's disease
Mason et al. FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions
Turrin et al. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide
Suzuki et al. Mesoderm induction by BMP-4 and-7 heterodimers
Bradbury et al. Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization.
Burchardt et al. Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans
DE60022478T2 (de) Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen
Ito et al. A quantitative assay using basement membrane extracts to study tumor angiogenesis in vivo
Masson et al. Tumor necrosis factor receptor associated factor 4 (TRAF4) expression pattern during mouse development
Sakata et al. Induction of infarct tolerance by platelet-derived growth factor against temporary focal ischemia
DE69920921T2 (de) Leptin vermittelte geninduktion
Dahiya et al. mRNA and protein expression of nitric oxide synthase and adrenoceptor alpha 1 in young and old rat penile tissues
Bugra et al. Acidic and basic fibroblast growth factor messenger RNA and protein show increased expression in adult compared to developing normal and dystrophic rat retina
Jung et al. A potential role of somatostatin and its receptor SSTR4 in the migration of hepatic oval cells
US7605128B2 (en) Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
Rushlow et al. Characterization of CArG-binding protein A initially identified by differential display
Caillaud et al. Treatment of PC12 cells by nerve growth factor, dexamethasone, and forskolin: Effects on cell morphology and expression of neurotensin and tyrosine hydroxylase
Palin et al. Characterization of interleukin-1 receptor antagonist isoform expression in the brain of lipopolysaccharide-treated rats
Giannini et al. EGF regulates a complex pattern of gene expression and represses smooth muscle differentiation during the neurotypic conversion of the neural-crest-derived TC-1S cell line
El-Husseini Basic fibroblast growth factor (bFGF) gene expression in rat brain during early postnatal development
WO2000066620A2 (en) Morphogen-induced enhancement of fertility
Hertel Novel players in neuroprotection and tissue reorganisation after hippocampal lesion
JP2003508493A (ja) Ｂｍｐ−９組成物およびコリン作動性ニューロンの分化誘導方法
AU2006203260A1 (en) Treatment of Central Nervous System Disorders by Use of PDGF or VEGF

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee